Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 26.4
(-2.22%)
SEK 26.4
(-2.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 60.3 Million SEK | 19.78% |
| 2022 | 50.34 Million SEK | 38.06% |
| 2021 | 36.46 Million SEK | -18.64% |
| 2020 | 44.82 Million SEK | 332.42% |
| 2019 | 10.36 Million SEK | 397.36% |
| 2018 | 2.08 Million SEK | -44.43% |
| 2017 | 3.75 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 71.89 Million SEK | 19.22% |
| 2024 Q3 | 123.58 Million SEK | 175.0% |
| 2024 Q2 | 75.71 Million SEK | 5.32% |
| 2023 Q3 | 56.71 Million SEK | 6.89% |
| 2023 Q4 | 60.3 Million SEK | 6.32% |
| 2023 Q1 | 59.62 Million SEK | 18.43% |
| 2023 Q2 | 53.06 Million SEK | -11.01% |
| 2023 FY | 60.3 Million SEK | 19.78% |
| 2022 Q3 | 49.94 Million SEK | -1.09% |
| 2022 Q2 | 50.49 Million SEK | 4.58% |
| 2022 Q1 | 48.28 Million SEK | 32.42% |
| 2022 FY | 50.34 Million SEK | 38.06% |
| 2022 Q4 | 50.34 Million SEK | 0.79% |
| 2021 Q1 | 41.88 Million SEK | -6.56% |
| 2021 FY | 36.46 Million SEK | -18.64% |
| 2021 Q4 | 36.46 Million SEK | -5.34% |
| 2021 Q3 | 38.52 Million SEK | 3.96% |
| 2021 Q2 | 37.05 Million SEK | -11.53% |
| 2020 FY | 44.82 Million SEK | 332.42% |
| 2020 Q3 | 36.21 Million SEK | -8.2% |
| 2020 Q2 | 39.44 Million SEK | 310.63% |
| 2020 Q1 | 9.6 Million SEK | -7.32% |
| 2020 Q4 | 44.82 Million SEK | 23.78% |
| 2019 Q4 | 10.36 Million SEK | 0.0% |
| 2019 FY | 10.36 Million SEK | 397.36% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 FY | 2.08 Million SEK | -44.43% |
| 2017 FY | 3.75 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | 3 Million SEK | -1910.067% |
| Biovica International AB (publ) | 7.82 Million SEK | -670.337% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Cyxone AB (publ) | 858 Thousand SEK | -6928.205% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -3424.372% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -146.251% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Intervacc AB (publ) | 181 Thousand SEK | -33216.022% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 73.949% |
| Lipum AB (publ) | 1.76 Million SEK | -3324.304% |
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -274.616% |
| Ziccum AB (publ) | 857 Thousand SEK | -6936.406% |
| BioArctic AB (publ) | 4.97 Million SEK | -1111.127% |
| Genovis AB (publ.) | 79.32 Million SEK | 23.976% |
| Camurus AB (publ) | 24.5 Million SEK | -146.06% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -118.755% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -1106.04% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | -63.829% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 15.554% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -14122.17% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -1864.235% |
| Amniotics AB (publ) | 2.58 Million SEK | -2237.287% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -5930.2% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 93.841% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 93.043% |
| Biosergen AB | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -192.572% |
| Corline Biomedical AB | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -8954.354% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 44.473% |
| BioInvent International AB (publ) | 23.24 Million SEK | -159.43% |
| SynAct Pharma AB | 637 Thousand SEK | -9366.562% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -6994.353% |
| Alzinova AB (publ) | 800 Thousand SEK | -7437.75% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -5583.506% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 43.371% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -7700.228% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 33.544% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -96.603% |